Drug Profile
Research programme: Muller cell therapies - Apollo Therapeutics
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Apollo Therapeutics
- Developer Apollo Therapeutics; University College London
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Retinal-disorders in United Kingdom
- 22 Feb 2017 Preclinical trials in Retinal disorders in United Kingdom (unspecified route)